Hemophilia B With Inhibitor
14
1
2
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
21.4%
3 terminated out of 14 trials
72.7%
-13.8% vs benchmark
29%
4 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors
ATHN 7: Hemophilia Natural History Study
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
A Phase I of SS109 in Hemophilia A or and B With Inhibitors
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.